论文部分内容阅读
目的:对比拉米夫定及阿昔洛韦对激素治疗的肾病综合征患者乙肝病毒复制的有效性。方法:10例肾病综合征伴乙肝病毒标志物阳性患者口服足量泼尼松或甲基泼尼松龙同时,分别口服拉米夫定及阿昔洛韦治疗三个月以上,观察血清乙型肝炎病毒脱氧核糖核酸(Hepatitis B Virus Deoxyribonucleic Acid, HBV-DNA)、乙型肝炎病毒标志物、肝功能变化。结果:1、拉米夫定组肾病综合征伴乙肝病毒标志物阳性5例中(HBsAg、HBeAg阳性1例,大三阳4例),给予拉米夫定治疗后3个月血清HBV-DNA滴度明显下降(P<0.01,治疗
OBJECTIVE: To compare the effectiveness of lamivudine and acyclovir in hepatitis B virus replication in patients with steroid-treated nephrotic syndrome. Methods: Ten patients with nephrotic syndrome and hepatitis B virus (HBV) positive were given oral prednisone or methylprednisolone orally at the same time, and lamivudine and acyclovir were given orally for more than three months respectively. Serum B Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA), hepatitis B virus markers, changes in liver function. In lamivudine group, nephrotic syndrome and hepatitis B virus were positive in 5 cases (HBsAg, HBeAg-positive in 1 case and Dansanyang in 4 cases), serum HBV-DNA in 3 months after lamivudine treatment Titers decreased significantly (P <0.01, treatment